GuidelineClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2021
SEOM Clinical Guideline of management of soft-tissue sarcoma (2020).
Guideline in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.
- Assessing Treatment Response in Soft Tissue Sarcoma Using Dynamic Contrast-Enhanced MRI: A Systematic Review.Korean journal of radiology · 2026Pooled it
- Apparent diffusion coefficient metrics for treatment response assessment in soft tissue sarcoma: Reproducibility and prognostic value of whole-tumor and sub-regional analysis.Skeletal radiology · 2026Article
- Overall survival of patients with localized soft tissue sarcoma treated with or without adjuvant chemotherapy (DEEPSARC): a real world nationwide retrospective cohort study in France.EClinicalMedicine · 2026Article
- Review
- Cytokeratin-Positive Pleomorphic Chest Wall Sarcoma Mimicking MPNST: A Case Report.Cancer management and research · 2026Article
- Case Report: A case series on actionable genomic alterations guiding effective targeted therapy in rare sarcomas.Frontiers in oncology · 2026Article
- Madelung Disease of the Scrotal Region: A Case Report.IJU case reports · 2026Article
- Retroperitoneal leiomyosarcoma invading the renal hilum: A case report and literature review.Radiology case reports · 2025Article
- Article
- Postoperative radiotherapy in patients with R0 resection of soft tissue sarcoma: results from the European sarcoma CONTICABASE analysis.The British journal of radiology · 2025Article
- Relative Dose Intensity of Trabectedin and Outcome of Advanced L-Sarcomas.Cancer medicine · 2025Article
- Beyond the benign: A rare case report of myxoid pleomorphic liposarcoma.Radiology case reports · 2025Article
- Undifferentiated Pleomorphic Sarcoma of Laryngeal Ventricle: A Case Report.Oman medical journal · 2025Article
- Immune monitoring of trabectedin therapy in refractory soft tissue sarcoma patients - the IMMUNYON study.Frontiers in immunology · 2025Article
- MAPK-targeted therapies in non-gastrointestinal stromal tumor soft tissue sarcomas: current landscape and future directions.Frontiers in oncology · 2025Review
- Review
- A practical risk stratification system based on ultrasonography and clinical characteristics for predicting the malignancy of soft tissue masses.Insights into imaging · 2024Article
- Real-world data on the management of pazopanib-induced liver toxicity in routine care of renal cell cancer and soft tissue sarcoma patients.Cancer chemotherapy and pharmacology · 2024Observational
- Efficacies of anlotinib monotherapy versus gemcitabine-based chemotherapy for patients with advanced soft tissue sarcoma after the failure of anthracycline-based chemotherapy.Journal of cancer research and clinical oncology · 2024Article
- Assessing the methodological strengths and limitations of the Spanish Society of Medical Oncology (SEOM) guidelines: a critical appraisal using AGREE II and AGREE-REX tool.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 10 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Soft-tissue sarcomas constitute an uncommon and heterogeneous group of tumors of mesenchymal origin. Diagnosis, treatment, and management should be performed by an expert multidisciplinary team. MRI/CT of the primary tumor and biopsy is mandatory before any treatment. Wide surgical resection with tumor-free tissue margin is the mainstay for localized disease. Radiotherapy is indicated in large, deep, high-grade tumors, or after marginal resection not suitable for re-excision. Perioperative chemotherapy should be discussed for high-risk sarcomas of the extremities and trunk-wall. In the case of oligometastatic disease, patients should be considered for local therapies. First-line treatment with anthracyclines (or in combination with ifosfamide) is the treatment of choice. Other drugs have shown activity in second-line therapy and in specific histological subtypes but options are limited and thus, a clinical trial should always be discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.